Literature DB >> 21177780

ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate.

Valentin David1, Aline Martin, Anne-Marie Hedge, Marc K Drezner, Peter S N Rowe.   

Abstract

Increased acidic serine aspartate-rich MEPE-associated motif (ASARM) peptides cause mineralization defects in X-linked hypophosphatemic rickets mice (HYP) and "directly" inhibit renal phosphate uptake in vitro. However, ASARM peptides also bind to phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PHEX) and are a physiological substrate for this bone-expressed, phosphate-regulating enzyme. We therefore tested the hypothesis that circulating ASARM peptides also "indirectly" contribute to a bone-renal PHEX-dependent hypophosphatemia in normal mice. Male mice (n = 5; 12 wk) were fed for 8 wk with a normal phosphorus and vitamin D(3) diet (1% P(i) diet) or a reduced phosphorus and vitamin D(3) diet (0.1% P(i) diet). For the final 4 wk, transplantation of mini-osmotic pumps supplied a continuous infusion of either ASARM peptide (5 mg·day(-1)·kg(-1)) or vehicle. HYP, autosomal recessive hypophosphatemic rickets (ARHR), and normal mice (no pumps or ASARM infusion; 0.4% P(i) diet) were used in a separate experiment designed to measure and compare circulating ASARM peptides in disease and health. ASARM treatment decreased serum phosphate concentration and renal phosphate cotransporter (NPT2A) mRNA with the 1% P(i) diet. This was accompanied by a twofold increase in serum ASARM and 1,25-dihydroxy vitamin D(3) [1,25 (OH)(2)D(3)] levels without changes in parathyroid hormone. For both diets, ASARM-treated mice showed significant increases in serum fibroblast growth factor 23 (FGF23; +50%) and reduced serum osteocalcin (-30%) and osteopontin (-25%). Circulating ASARM peptides showed a significant inverse correlation with serum P(i) and a significant positive correlation with fractional excretion of phosphate. We conclude that constitutive overexpression of ASARM peptides plays a "component" PHEX-independent part in the HYP and ARHR hypophosphatemia. In contrast, with wild-type mice, ASARM peptides likely play a bone PHEX-dependent role in renal phosphate regulation and FGF23 expression. They may also coordinate FGF23 expression by competitively modulating PHEX/DMP1 interactions and thus bone-renal mineral regulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21177780      PMCID: PMC3064126          DOI: 10.1152/ajprenal.00304.2010

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  61 in total

Review 1.  Hypophosphatemic rickets.

Authors:  Marc K Drezner
Journal:  Endocr Dev       Date:  2003

2.  Renal calcification in mice homozygous for the disrupted type IIa Na/Pi cotransporter gene Npt2.

Authors:  Hien Chau; Sherif El-Maadawy; Marc D McKee; Harriet S Tenenhouse
Journal:  J Bone Miner Res       Date:  2003-04       Impact factor: 6.741

3.  Human recombinant endopeptidase PHEX has a strict S1' specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein.

Authors:  Marcelo Campos; Constance Couture; Izaura Y Hirata; Maria A Juliano; Thomas P Loisel; Philippe Crine; Luiz Juliano; Guy Boileau; Adriana K Carmona
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

4.  Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone.

Authors:  L Argiro; M Desbarats; F H Glorieux; B Ecarot
Journal:  Genomics       Date:  2001-06-15       Impact factor: 5.736

5.  Role of abnormal neutral endopeptidase-like activities in Hyp mouse bone cells in renal phosphate transport.

Authors:  Stéphanie G Dubois; Andréa Frota Ruchon; Aline Delalandre; Guy Boileau; Daniel Lajeunesse
Journal:  Am J Physiol Cell Physiol       Date:  2002-11       Impact factor: 4.249

6.  Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals.

Authors:  J R Hoyer; J R Asplin; L Otvos
Journal:  Kidney Int       Date:  2001-07       Impact factor: 10.612

7.  Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression.

Authors:  Xiuying Bai; Dengshun Miao; Dibiyendu Panda; Scott Grady; Marc D McKee; David Goltzman; Andrew C Karaplis
Journal:  Mol Endocrinol       Date:  2002-12

8.  Inhibition of MEPE cleavage by Phex.

Authors:  Rong Guo; Peter S N Rowe; Shiguang Liu; Leigh G Simpson; Zhou-Sheng Xiao; L Darryl Quarles
Journal:  Biochem Biophys Res Commun       Date:  2002-09-13       Impact factor: 3.575

9.  Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX.

Authors:  Shiguang Liu; Rong Guo; Leigh G Simpson; Zhou-Sheng Xiao; Charles E Burnham; L Darryl Quarles
Journal:  J Biol Chem       Date:  2003-07-21       Impact factor: 5.157

10.  MEPE has the properties of an osteoblastic phosphatonin and minhibin.

Authors:  P S N Rowe; Y Kumagai; G Gutierrez; I R Garrett; R Blacher; D Rosen; J Cundy; S Navvab; D Chen; M K Drezner; L D Quarles; G R Mundy
Journal:  Bone       Date:  2004-02       Impact factor: 4.398

View more
  21 in total

Review 1.  FGF23 and Phosphate Wasting Disorders.

Authors:  Xianglan Huang; Yan Jiang; Weibo Xia
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

Review 2.  The osteocyte: an endocrine cell ... and more.

Authors:  Sarah L Dallas; Matthew Prideaux; Lynda F Bonewald
Journal:  Endocr Rev       Date:  2013-04-23       Impact factor: 19.871

3.  Vitamin D represses dentin matrix protein 1 in cementoblasts and osteocytes.

Authors:  F H Nociti; B L Foster; A B Tran; D Dunn; R B Presland; L Wang; N Bhattacharyya; M T Collins; M J Somerman
Journal:  J Dent Res       Date:  2013-12-11       Impact factor: 6.116

Review 4.  Congenital Conditions of Hypophosphatemia Expressed in Adults.

Authors:  Gemma Marcucci; Maria Luisa Brandi
Journal:  Calcif Tissue Int       Date:  2020-05-14       Impact factor: 4.333

Review 5.  Regulation and function of the FGF23/klotho endocrine pathways.

Authors:  Aline Martin; Valentin David; L Darryl Quarles
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

6.  Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice.

Authors:  A Martin; V David; H Li; B Dai; J Q Feng; L D Quarles
Journal:  Mol Endocrinol       Date:  2012-08-28

Review 7.  Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.

Authors:  Peter S N Rowe
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2012       Impact factor: 1.807

Review 8.  Osteocytes: master orchestrators of bone.

Authors:  Mitchell B Schaffler; Wing-Yee Cheung; Robert Majeska; Oran Kennedy
Journal:  Calcif Tissue Int       Date:  2013-09-17       Impact factor: 4.333

9.  Do ASARM peptides play a role in nephrogenic systemic fibrosis?

Authors:  Peter S N Rowe; Lesya V Zelenchuk; Jennifer S Laurence; Phil Lee; William M Brooks; Ellen T McCarthy
Journal:  Am J Physiol Renal Physiol       Date:  2015-09-02

10.  Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif.

Authors:  Lesya V Zelenchuk; Anne-Marie Hedge; Peter S N Rowe
Journal:  Bone       Date:  2015-06-04       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.